Furthermore, research has demonstrated the elevated expression of MCM2 in various cancers, including breast cancer [43] and hepatocellular carcinoma [44], suggesting that MCM2 may represent a viable therapeutic target for numerous cancer types. This evidence concerns the gene MCM2 and hepatocellular carcinoma.